OralDNA Labs Inc. recently enhanced its MyPerioPath patient lab report with the addition of an expanded section called “MyPerioProgress.” The MyPerioPath salivary diagnostic test identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease and helps support clinicians with better risk assessment and personalized treatment options for more predictable patient outcomes.
The MyPerioProgress section is a new third page that is automatically generated for patients who have taken the MyPerioPath test more than once. It provides a series of graphs that enable dental clinicians to compare current MyPerioPath test results with previous results. This comparison can provide valuable insight into the progress of the patient’s current course of periodontal disease treatment.
According to MyPerioPath test user Dr. Doug Thompson, of Bloomfield Hills, Mich., “MyPerioProgress provides periodontal disease treatment benchmarks that enable me to closely monitor patient progress over time and modify the treatment, if needed. It is also a great tool for explaining the course of treatment to the patient and for increasing patient acceptance and compliance.”
The following is a partial list of important observations that are illustrated with MyPerioProgress:
- An increase or decrease in the reported pathogen(s), especially high-risk bacteria.
- The common finding of an increase in the quantity of low-risk bacteria (Capnocytophaga species [Cs]) following a successful course of treatment. This spike in Cs is typically a temporary phenomenon.
- Changes in clinical signs of pocket depth, bleeding, or type of infection (generalized or localized) in the context of similar changes in bacterial loads.
By monitoring the above findings, MyPerioProgress will be an added resource to help dental clinicians assess if their patients are trending towards health or continued disease. According to OralDNA Labs general manager Ken Clarke. “MyPerioProgress was designed to help clinicians determine with increased accuracy whether or not the desired end point of therapy has been reached. This determination is achieved by evaluating the clinical signs and symptoms of periodontal disease, and by factoring the risk for disease progression from oral bacteria."
OralDNA Labs Inc. provides clinical tests for the detection and prognosis of disease at an earlier, more treatable stage:
- MyPerioPath identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease and helps support clinicians with better risk assessment and personalized treatment options for more predictable patient outcomes.
- MyPerioID PST identifies individual genetic susceptibility to periodontal disease and enables clinicians to establish which patients are at increased risk for more severe periodontal infections due to an exaggerated immune response.
- OraRisk HPV is a non-invasive, easy-to-use screening tool to identify the type(s) of oral HPV, a mucosal viral infection that could potentially lead to oral cancer, and in turn, enables the clinician to establish increased risk for oral cancer and determine appropriate referral and monitoring conditions.
